The Worldwide Pharmacogenomics Services Industry is Expected to Reach Billion by 2031 ResearchAndMarketscom
DUBLIN, January 19, 2022--(BUSINESS WIRE)--The "Pharmacogenomics Services Market - A Global and Regional Analysis: Focus on Service, Technology, Application, End User, and Country-Wise Analysis - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering. The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031. The market is driven by certain factors, including increasing prevalence of infectious diseases and various types of cancer, increasing adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. Currently, the pharmacogenomics services industry is witnessing an upsurge due to the increasing prevalence of infectious diseases and various types of cancer, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. Furthermore, companies focus on developing pharmacogenomic tests based on advanced molecular assay technologies, which is expected to further support physicians in offering better informed clinical decisions. The development of advanced pharmacogenomic tests also enables the research community to establish effective strategies for discovering novel biomarkers associated with various diseases, which could be harnessed to develop targeted therapies. Within the research report, the market is segmented on the basis of service, technology, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
LLC Mesa Laboratories, Inc.
Dynamic DNA Laboratories
F. Hoffmann-La Roche Ltd.
geneOmbio Technologies Pvt Ltd.
Exact Sciences Corporation Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Precipio 23andMe, Inc.
DiaCarta, Inc. OPKO Health
Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally
Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
Increasing Rate of Adverse Drug Reaction
Surge in Usage of Pharmacogenomics for Drug Discovery and Development
Lack of Use of Available Data for Drug Development Initiatives
Lack of High Complexity Testing Centers
Difficulties in Detecting Gene Variation Affecting Drug Response
Regulatory Challenges for Direct-to-Consumer (DTC) Pharmacogenomics Companies
Massive Scope for Adoption of Pharmacogenomics in Emerging Nations
Technological Advancements in Molecular Techniques for Pharmacogenomic Diagnostic Tests
Rise of Direct-to-Consumer (DTC) Testing Services
Key Questions Answered in the Report
How are pharmacogenomics services revolutionizing clinical diagnostics and translational research?
What are the major market drivers, challenges, and opportunities in the global pharmacogenomics services market?
What are the underlying structures resulting in the emerging trends within the global pharmacogenomics services market?
How did the COVID-19 pandemic impact the global pharmacogenomics services ecosystem?
What are key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
What are the key regulatory implications in developed and developing regions pertaining to the use of pharmacogenomics services?
What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments?
What are the growth opportunities for the pharmacogenomics services companies in the region of their operation?
Who are the leading players with significant offerings in the global pharmacogenomics services market?
Which companies are anticipated to be highly disruptive in the future, and why?